PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology
20 Agosto 2024 - 10:00AM
PRISM MarketView announces the release of an illuminating
interview with Oncocyte (Nasdaq:OCX) CFO Andrea S. James, who
sheds light on her personal career path and the experiences that
led to her senior role with the molecular diagnostics technology
company.
Oncocyte is a market disruptor with a mission to democratize
access to molecular diagnostic testing to improve patient outcomes.
The company is investing in developing products to serve the
separate verticals of organ transplant testing and
oncology. James states, “I built my career on the concept of
disruptive technology, and I believe that what Oncocyte is offering
is truly disruptive in its target category.”
During a discussion with PRISM MarketView, James touts the
company’s unique molecular diagnostic kitted tests, which can be
performed locally at hospitals and labs, empowering facilities to
conduct complex molecular diagnostics in-house. “We believe
that the market wants options that are more accessible,
cost-effective, and scalable,” she shares. “Our thesis is that this
democratization can help improve patient outcomes, particularly in
areas like organ transplantation where early detection of
complications is critical.”
James also discusses her pivot from Wall Street to Tesla: “I
loved both people and spreadsheets, I joked, so where does that
leave me? I ended up assisting Tesla with its investor relations
and found that I really loved it. I liked marrying business
strategy and understanding the P&L with investor communication
and also maintaining relationships with Tesla’s shareholders.”
Her leadership is predicated on the idea that CFOs of public
companies need to go beyond finance subject matter expertise to
anticipating strategic decisions and “always thinking in terms of
the business we want to build, and why, and how we are going to get
there. I am constantly evaluating where to invest to help the
company thrive. But being a CFO goes way beyond baseline skills.
The world doesn’t fit neatly into a spreadsheet. We may have to
understand the complexity, but our job is to help make things
simple for everyone else; to help make decisions with clarity.”
The full interview can be found at:
https://prismmarketview.com/climbing-the-ladder-of-executive-leadership-insights-from-andrea-s-james-chief-financial-officer-of-oncocyte/
About Oncocyte
Oncocyte is a molecular diagnostics technology company. The
company’s tests are designed to help provide clarity and confidence
to physicians and their patients. VitaGraft™ is a clinical
blood-based solid organ transplantation monitoring test.
GraftAssure™ is a research use only (RUO) blood-based solid organ
transplantation monitoring test. DetermaIO™ is a gene expression
test that assesses the tumor microenvironment to predict response
to immunotherapies. DetermaCNI™ is a blood-based monitoring tool
for monitoring therapeutic efficacy in cancer patients. For more
information about Oncocyte, please
visit https://oncocyte.com/. For more information about our
products, please visit the following web pages:
VitaGraft Kidney™
- https://oncocyte.com/vitagraft-kidney/VitaGraft Liver™
- https://oncocyte.com/vitagraft-liver/GraftAssure™
- https://oncocyte.com/graftassure/DetermaIO™
- https://oncocyte.com/determa-io/DetermaCNI™
- https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™ and DetermaCNI™ are
trademarks of Oncocyte Corporation.
About PRISM MarketView:Established in 2020,
PRISM MarketView is dedicated to the monitoring and analysis of
small cap stocks in burgeoning sectors. We deliver up-to-the-minute
financial market news, provide comprehensive investor tools and
foster a dynamic investor community. Central to our offerings are
proprietary indexes that observe emerging sectors, including
biotech, clean energy, next-generation tech, medical devices and
beyond. Visit us at prismmarketview.com and follow us
on X.
PRISM MarketView does not provide investment advice.
Disclaimer
This communication was produced by PRISM MarketView, an
affiliate of PCG Advisory Inc., (together "PCG"). PCG is not a
registered or licensed broker-dealer nor investment adviser. No
information contained in this communication constitutes an offer to
sell, a solicitation of an offer to buy, or a recommendation of any
security. PCG may be compensated by respective clients for
publicizing information relating to its clients’ securities.
See www.pcgadvisory.com/disclosures.
Contact:PRISM
MarketViewinfo@prismmarketview.com646-863-6341
Oncocyte (NASDAQ:OCX)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Oncocyte (NASDAQ:OCX)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024